Supply Chain Intelligence

Design Therapeutics, Inc. Supply Chain

DSGN supply chain intelligence for Design Therapeutics, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.

DSGN ·Last updated 2026-07-30 · Interactive map →

Data compiled by Redley Lamar · ChainSifter Intelligence

3Suppliers
2Customers
2Debt Items
20Related Chains

Design Therapeutics, Inc. Suppliers

TickerNameConfidenceEvidence
WISCONSIN-ALUMNI-RESEARCH-FOUNDATION WISCONSIN-ALUMNI-RESEARCH-FOUNDATION 92% Under the License Agreement, the Company licensed the exclusive, worldwide, royalty-bearing, sublicensable rights to certain WARF patents and the nonexclusive worldwide rights to certain know-how to …
LXEO Lexeo Therapeutics, Inc. 72% Reciprocal relationship from LXEO graph: s, obtain marketing approval and ultimately commercialize them. If we are unable to or experience significant delays in doing so, our business will be materia…
TRDA Entrada Therapeutics, Inc. 72% Reciprocal relationship from TRDA graph: Reciprocal relationship from DSGN graph: Reciprocal relationship from TRDA graph: f treatment with our therapeutics in relation to alternative treatments and …

Design Therapeutics, Inc. Customers

TickerNameConfidenceEvidence
LXEO Lexeo Therapeutics, Inc. 72% Reciprocal relationship from LXEO graph: ply, if any, could be identified and qualified. We may be unable to find a sufficient alternative supply channel in a reasonable time or on commercially reaso…
TRDA Entrada Therapeutics, Inc. 72% Reciprocal relationship from TRDA graph: everal risks, including disruptions in supply, price increases or late deliveries. There are, in general, relatively few alternative sources of supply for sub…

Design Therapeutics, Inc. Debt Obligations

InstrumentDescriptionConfidenceEvidence
DSGN-DEBT-9147 Xbrl Convertible 90% xbrl convertible detail from xbrl 2021-12-31.
DSGN-DEBT Debt stack $2.7M 90% Market cache reports total debt of $2.7M.

Design Therapeutics, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Design Therapeutics, Inc..

Design Therapeutics, Inc. Ownership

HolderNameConfidenceEvidence
DSGN-OWNER-SR-ONE-CAPITAL-MANAGEMENT-LP SR One Capital Management, LP 90% 13F overlay lists SR One Capital Management, LP as top holder; 125 tracked holders.

Design Therapeutics, Inc. Extended Supply Chain Network

TickerNameChain IndexHopsRelationship Types
PSNL Personalis, Inc. 100.00 2
AKTS Aktis Oncology, Inc. 100.00 2
BLRX BioLineRx Ltd. 100.00 2
CCEP Coca-Cola Europacific Partners PLC 100.00 2
CYTOF Altamira Therapeutics Ltd. 100.00 2
ALXO ALX Oncology Holdings Inc. 100.00 2
CTNM Contineum Therapeutics, Inc. 100.00 2
WHWK Whitehawk Therapeutics, Inc. 100.00 2
CPRX Catalyst Pharmaceuticals, Inc. 100.00 2
ANRO Alto Neuroscience, Inc. 100.00 2
AXSM Axsome Therapeutics, Inc. 100.00 2
BNBX BNB Plus Corp. 100.00 2
CTMX CytomX Therapeutics, Inc. 100.00 2
BIOA BioAge Labs, Inc. 100.00 2
CYTK Cytokinetics, Incorporated 100.00 2
FHTX Foghorn Therapeutics Inc. 100.00 2
ANL Adlai Nortye Ltd. 100.00 2
CBIO Crescent Biopharma, Inc. 100.00 2
DAWN Day One Biopharmaceuticals Inc 100.00 2
AZN AstraZeneca PLC 100.00 2
View DSGN supply chain intel →

Explore the full interactive supply chain map for Design Therapeutics, Inc..

Open DSGN supply chain map →
ChainSifter · Guerilla Finance Terms Disclaimer ← Back to Map